Literature DB >> 33514660

Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques.

Dariusz K Murakowski1,2, John P Barton2,3, Lauren Peter4, Abishek Chandrashekar4, Esther Bondzie4, Ang Gao3, Dan H Barouch5,4, Arup K Chakraborty6,2,3,7,8.   

Abstract

An effective vaccine that can protect against HIV infection does not exist. A major reason why a vaccine is not available is the high mutability of the virus, which enables it to evolve mutations that can evade human immune responses. This challenge is exacerbated by the ability of the virus to evolve compensatory mutations that can partially restore the fitness cost of immune-evading mutations. Based on the fitness landscapes of HIV proteins that account for the effects of coupled mutations, we designed a single long peptide immunogen comprising parts of the HIV proteome wherein mutations are likely to be deleterious regardless of the sequence of the rest of the viral protein. This immunogen was then stably expressed in adenovirus vectors that are currently in clinical development. Macaques immunized with these vaccine constructs exhibited T-cell responses that were comparable in magnitude to animals immunized with adenovirus vectors with whole HIV protein inserts. Moreover, the T-cell responses in immunized macaques strongly targeted regions contained in our immunogen. These results suggest that further studies aimed toward using our vaccine construct for HIV prophylaxis and cure are warranted.

Entities:  

Keywords:  HIV; fitness landscape; subunit vaccines

Mesh:

Substances:

Year:  2021        PMID: 33514660      PMCID: PMC7865178          DOI: 10.1073/pnas.2022496118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Direct-coupling analysis of residue coevolution captures native contacts across many protein families.

Authors:  Faruck Morcos; Andrea Pagnani; Bryan Lunt; Arianna Bertolino; Debora S Marks; Chris Sander; Riccardo Zecchina; José N Onuchic; Terence Hwa; Martin Weigt
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

Review 2.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 3.  Rational design of vaccine targets and strategies for HIV: a crossroad of statistical physics, biology, and medicine.

Authors:  Arup K Chakraborty; John P Barton
Journal:  Rep Prog Phys       Date:  2017-01-06

4.  ACE: adaptive cluster expansion for maximum entropy graphical model inference.

Authors:  J P Barton; E De Leonardis; A Coucke; S Cocco
Journal:  Bioinformatics       Date:  2016-06-21       Impact factor: 6.937

5.  Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.

Authors:  Beatrice Ondondo; Hayato Murakoshi; Genevieve Clutton; Sultan Abdul-Jawad; Edmund G-T Wee; Hiroyuki Gatanaga; Shinichi Oka; Andrew J McMichael; Masafumi Takiguchi; Bette Korber; Tomáš Hanke
Journal:  Mol Ther       Date:  2016-01-08       Impact factor: 11.454

Review 6.  The T-cell response to HIV.

Authors:  Bruce Walker; Andrew McMichael
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

7.  Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.

Authors:  Lindsey R Baden; Etienne Karita; Gaudensia Mutua; Linda-Gail Bekker; Glenda Gray; Liesl Page-Shipp; Stephen R Walsh; Julien Nyombayire; Omu Anzala; Surita Roux; Fatima Laher; Craig Innes; Michael S Seaman; Yehuda Z Cohen; Lauren Peter; Nicole Frahm; M Juliana McElrath; Peter Hayes; Edith Swann; Nicole Grunenberg; Maria Grazia-Pau; Mo Weijtens; Jerry Sadoff; Len Dally; Angela Lombardo; Jill Gilmour; Josephine Cox; Raphael Dolin; Patricia Fast; Dan H Barouch; Dagna S Laufer
Journal:  Ann Intern Med       Date:  2016-02-02       Impact factor: 25.391

8.  Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.

Authors:  Donn J Colby; Michal Sarnecki; Dan H Barouch; Somporn Tipsuk; Daniel J Stieh; Eugène Kroon; Alexandra Schuetz; Jintana Intasan; Carlo Sacdalan; Suteeraporn Pinyakorn; Pornsuk Grandin; Hongshuo Song; Sodsai Tovanabutra; Zhanna Shubin; Dohoon Kim; Dominic Paquin-Proulx; Michael A Eller; Rasmi Thomas; Mark de Souza; Lindsay Wieczorek; Victoria R Polonis; Amélie Pagliuzza; Nicolas Chomont; Lauren Peter; Joseph P Nkolola; Johan Vingerhoets; Carla Truyers; Maria G Pau; Hanneke Schuitemaker; Nittaya Phanuphak; Nelson Michael; Merlin L Robb; Frank L Tomaka; Jintanat Ananworanich
Journal:  Nat Med       Date:  2020-03-23       Impact factor: 87.241

Review 9.  CD8+ T cells in HIV control, cure and prevention.

Authors:  David R Collins; Gaurav D Gaiha; Bruce D Walker
Journal:  Nat Rev Immunol       Date:  2020-02-12       Impact factor: 53.106

10.  Distinct viral reservoirs in individuals with spontaneous control of HIV-1.

Authors:  Chenyang Jiang; Xiaodong Lian; Ce Gao; Xiaoming Sun; Kevin B Einkauf; Joshua M Chevalier; Samantha M Y Chen; Stephane Hua; Ben Rhee; Kaylee Chang; Jane E Blackmer; Matthew Osborn; Michael J Peluso; Rebecca Hoh; Ma Somsouk; Jeffrey Milush; Lynn N Bertagnolli; Sarah E Sweet; Joseph A Varriale; Peter D Burbelo; Tae-Wook Chun; Gregory M Laird; Erik Serrao; Alan N Engelman; Mary Carrington; Robert F Siliciano; Janet M Siliciano; Steven G Deeks; Bruce D Walker; Mathias Lichterfeld; Xu G Yu
Journal:  Nature       Date:  2020-08-26       Impact factor: 69.504

View more
  2 in total

1.  Evolutionary modeling reveals enhanced mutational flexibility of HCV subtype 1b compared with 1a.

Authors:  Hang Zhang; Ahmed A Quadeer; Matthew R McKay
Journal:  iScience       Date:  2021-12-08

2.  Epistatic models predict mutable sites in SARS-CoV-2 proteins and epitopes.

Authors:  Juan Rodriguez-Rivas; Giancarlo Croce; Maureen Muscat; Martin Weigt
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-25       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.